The Global Liposomal Drug-Delivery System Market was valued at USD 3,328 Million in 2023 and is projected to reach USD 7,911.69 Million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 10.10% during the forecast period. This robust expansion is being driven by the increasing demand for targeted drug delivery in oncology, the growing adoption of liposomal formulations in vaccine development, and the rising need to improve the bioavailability of poorly water-soluble pharmaceutical compounds across both medical and cosmetic applications.

As the global pharmaceutical and biotechnology industries shift toward precision medicine and patient-centric treatment approaches, the spotlight is firmly on the key innovators who are engineering the next generation of drug delivery platforms. In this blog, we profile the Top 10 Companies in the Liposomal Drug-Delivery System Industry—a diverse mix of pharmaceutical technology firms, specialty chemical manufacturers, and biotech pioneers shaping the future of encapsulation science and targeted therapeutics.

---

📺️ 1. Lipoid Kosmetik AG

Headquarters: Steinhausen, Switzerland
Key Offering: Phospholipid-based liposomal systems for cosmetic and pharmaceutical applications

Lipoid Kosmetik is a globally recognized leader in the production of high-purity phospholipids and liposomal delivery systems. The company supplies both the cosmetics and pharmaceutical sectors with advanced lipid-based ingredients that enhance active ingredient penetration, stability, and skin bioavailability. Their deep expertise in lecithin chemistry and liposome technology positions them as a foundational supplier for premium personal care and drug delivery formulations worldwide.

Key Innovation Focus:

• Development of standardized phospholipid raw materials for liposome manufacturing

• Liposomal encapsulation solutions for vitamins, ceramides, and active cosmetic ingredients

• Strong regulatory compliance across European and global pharmaceutical standards

Download FREE Sample Report:
Liposomal Drug-delivery System Market – View in Detailed Research Report

---

️ 2. Croda International Plc

Headquarters: Snaith, East Yorkshire, United Kingdom
Key Offering: Lipid excipients, liposomal delivery systems for pharma and personal care

Croda International is a specialty chemical company with a strong presence in the liposomal and lipid nanoparticle space. The company has played a notable role in the development of lipid excipients used in mRNA vaccine delivery systems, which gained unprecedented global attention during the COVID-19 pandemic. Croda’s pharmaceutical division offers a broad portfolio of ionizable lipids, PEGylated lipids, and helper lipids critical to the construction of functional liposomal and lipid nanoparticle formulations.

Key Innovation Focus:

• Proprietary lipid excipients for mRNA and gene therapy delivery

• Partnerships with leading vaccine developers and biopharmaceutical companies

• Expanding manufacturing capacity for next-generation lipid nanoparticle components

---

️ 3. NOF CORPORATION

Headquarters: Tokyo, Japan
Key Offering: PEGylated lipids, phospholipids, and liposomal excipients

NOF Corporation is a leading Japanese manufacturer of specialty chemicals, with a well-established pharmaceutical division focused on lipid-based drug delivery. The company produces high-purity PEGylated phospholipids and other lipid components widely used in the formulation of liposomal drugs and lipid nanoparticles. NOF’s SUNBRIGHT® series of PEG lipids has become an industry benchmark for liposome surface modification, enabling extended circulation times and targeted delivery in clinical applications.

Key Innovation Focus:

• SUNBRIGHT® PEGylated lipid portfolio for targeted liposomal formulations

• Active R&D collaboration with pharmaceutical developers globally

• Commitment to cGMP-compliant lipid manufacturing for clinical and commercial supply

---

️ 4. Lucas Meyer Cosmetics

Headquarters: Mitry-Mory, France
Key Offering: Liposomal active ingredients for cosmetics and dermatology

Lucas Meyer Cosmetics, a subsidiary of International Flavors & Fragrances (IFF), specializes in the development of cutting-edge cosmetic ingredients with a particular emphasis on liposome-encapsulated actives. The company’s expertise lies in encapsulating skin-beneficial compounds such as peptides, vitamins, and botanical extracts into stable liposomal vehicles that dramatically improve dermal penetration and ingredient longevity. Their formulations are adopted widely by premium skincare and dermocosmetic brands globally.

Key Innovation Focus:

• Encapsulation of high-value cosmetic actives including peptides and vitamins

• Sustainable sourcing and green chemistry principles in liposome manufacturing

• Clinical validation of efficacy for dermatological cosmetic applications

Download FREE Sample Report:
Liposomal Drug-delivery System Market – View in Detailed Research Report

---

️ 5. Nippon Fine Chemical Co., Ltd.

Headquarters: Osaka, Japan
Key Offering: Phospholipids, ceramides, and liposomal raw materials

Nippon Fine Chemical is a specialized manufacturer of high-purity phospholipids, ceramides, and other lipid-based materials used extensively in liposomal drug delivery and cosmetic formulations. The company is a trusted supplier to both pharmaceutical and personal care industries across Asia and globally, offering lipid ingredients that meet stringent quality and purity requirements. Their ceramide and sphingolipid portfolio has particular relevance in skin barrier restoration formulations and liposomal cosmetic systems.

Key Innovation Focus:

• Specialty ceramide and phospholipid production for cosmetic liposome systems

• Technical support for liposome formulation development

• Quality assurance aligned with Japanese pharmaceutical and cosmetic industry standards

---

5️⃣ 6. Lipotec S.A.U. (Lubrizol Life Science)

Headquarters: Barcelona, Spain
Key Offering: Liposome-encapsulated peptides and active cosmetic ingredients

Lipotec, now part of Lubrizol Life Science Beauty, is a leading innovator in cosmetic biotechnology with a strong focus on liposomal delivery of bioactive peptides for anti-aging and skin health applications. The company’s flagship peptide products, encapsulated in liposomal carriers, are used by renowned cosmetic brands across Europe, North America, and Asia-Pacific. Lipotec’s research-driven approach combines molecular biology with advanced encapsulation science to deliver clinically substantiated cosmetic actives.

Key Innovation Focus:

• Proprietary peptide-liposome combinations for anti-aging and skin renewal

• Extensive in vitro and clinical testing for product validation

• Broad global distribution network serving premium cosmetic manufacturers

---

4️⃣ 7. Kewpie Corporation

Headquarters: Tokyo, Japan
Key Offering: Egg yolk-derived phospholipids and liposomal ingredients

Kewpie Corporation, widely recognized for its food products, also operates a significant specialty ingredients division focused on phospholipid extraction and liposomal technology. The company produces high-purity egg yolk lecithin and derived phospholipids used as essential building blocks in liposome formulation for both pharmaceutical and cosmetic applications. Kewpie’s phospholipid raw materials are valued for their natural origin, high purity, and excellent biocompatibility, making them a preferred choice among liposome manufacturers globally.

Key Innovation Focus:

• High-purity egg-derived phospholipid production for pharmaceutical-grade liposomes

• Investment in purification technologies to enhance lipid quality and consistency

• Support for liposomal formulation research through ingredient supply and technical guidance

---

3️⃣ 8. Creative Biostructure

Headquarters: Shirley, New York, USA
Key Offering: Custom liposome preparation, lipid nanoparticle development services

Creative Biostructure is a contract research organization (CRO) specializing in membrane protein research, liposome preparation, and lipid nanoparticle (LNP) development. The company offers end-to-end liposome formulation services to pharmaceutical and biotech clients, ranging from feasibility studies and encapsulation optimization to analytical characterization and scale-up support. Their Lipo-Meso™ liposome technology platform is designed to support drug encapsulation across a wide range of therapeutic molecules, including small molecules, peptides, and nucleic acids.

Key Innovation Focus:

• Custom liposome engineering for pharmaceutical research and preclinical applications

• Lipid nanoparticle design and development for RNA-based therapeutics

• Analytical services including particle sizing, encapsulation efficiency, and stability testing

Read Full Report:
Liposomal Drug-delivery System Market – View in Detailed Research Report

---

2️⃣ 9. KYOWA PHARMA CHEMICAL CO., LTD.

Headquarters: Toyama, Japan
Key Offering: Pharmaceutical-grade phospholipids and liposomal excipients

KYOWA PHARMA CHEMICAL is a well-established Japanese producer of pharmaceutical-grade phospholipids and lipid-based excipients used in liposomal drug formulations. The company serves both domestic and international pharmaceutical manufacturers, supplying consistently high-purity lipid materials that comply with pharmacopeial and regulatory standards in Japan, the United States, and Europe. Their product portfolio includes soybean-derived and synthetic phospholipids tailored for liposome assembly and drug encapsulation in injectable and topical drug formulations.

Key Innovation Focus:

• cGMP-compliant phospholipid manufacturing for injectable liposomal drug products

• Broad lipid portfolio covering both natural and synthetic phospholipid classes

• Long-standing technical partnerships with Japanese and global pharma manufacturers

---

1️⃣ 10. Nanohealth Biotech

Headquarters: Taiwan
Key Offering: Liposomal nutraceuticals, cosmetic liposome systems, and drug delivery platforms

Nanohealth Biotech is an emerging yet influential player in the liposomal delivery space, specializing in the development and commercialization of liposomal formulations for nutraceutical, cosmetic, and pharmaceutical applications. The company leverages nanotechnology to produce stable, bioavailable liposomal products including liposomal vitamins, CoQ10, and other active compounds. Their proprietary nano-encapsulation platform enables high encapsulation efficiency and controlled release, catering to both B2B ingredient supply and finished product markets across Asia and internationally.

Key Innovation Focus:

• Proprietary nano-liposome technology for nutraceutical and cosmetic applications

• High-encapsulation-efficiency liposomal vitamins and antioxidants

• Expanding market presence across Asia-Pacific and emerging pharmaceutical markets

Read Full Report:
Liposomal Drug-delivery System Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Liposomal Drug Delivery Is Targeted, Smarter, and More Accessible

The liposomal drug-delivery system market is undergoing a profound transformation. While liposomal formulations have been used in clinical medicine for decades—most notably in cancer treatment with drugs like doxorubicin and amphotericin B—the landscape is now expanding rapidly into vaccine development, gene therapy, and advanced cosmetic science. The commercial success of lipid nanoparticle-based mRNA COVID-19 vaccines demonstrated to the world just how powerful and scalable lipid-based delivery platforms can be, and that breakthrough has triggered massive investment and innovation across the entire sector.

Furthermore, the growing prevalence of chronic diseases, rising cancer incidence globally, and increased patient demand for therapies with fewer side effects are all converging to accelerate the adoption of liposomal drug delivery. Because liposomes can protect sensitive drug molecules from degradation, control their release profiles, and direct them to specific target tissues, they represent one of the most clinically versatile and commercially promising platforms in modern pharmaceutical science. However, challenges remain around manufacturing scalability, formulation stability, and cost, which manufacturers are actively working to overcome through continuous R&D investment and process innovation.

📈 Key Trends Shaping the Market:

• Rapid expansion of lipid nanoparticle and liposomal platforms in mRNA therapeutics and gene editing applications

• Growing regulatory approvals for novel liposomal oncology drugs in the US, EU, and Asia-Pacific markets

• Increasing use of liposomal encapsulation in cosmeceuticals and premium skincare for enhanced active ingredient delivery

• Rising investments from global pharmaceutical companies into liposomal manufacturing infrastructure and formulation capabilities

• North America leading the market with a valuation of USD 1,023.83 Million in 2023, growing at a CAGR of 8.66% through 2032

Read Full Report:
Liposomal Drug-delivery System Market – View in Detailed Research Report

The companies profiled above are not only advancing the science of drug delivery—they’re reshaping the very foundation of how medicines and active ingredients reach their targets within the human body. From pharmaceutical giants supplying critical lipid excipients to innovative biotech firms developing next-generation encapsulation platforms, these market leaders are collectively driving the precision medicine revolution that the global healthcare industry so urgently needs.